Parkinson DR - Search Results

1

Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor.

LeMaistre CF, Meneghetti C, Rosenblum M, Reuben J, Parker K, Shaw J, Deisseroth A, Woodworth T, Parkinson DR. LeMaistre CF, et al. Among authors: parkinson dr. Blood. 1992 May 15;79(10):2547-54. Blood. 1992. PMID: 1586707 Free article. Clinical Trial.

2

Therapeutic effects of genetically engineered toxin (DAB486IL-2) in patient with chronic lymphocytic leukaemia.

LeMaistre CF, Rosenblum MG, Reuben JM, Parkinson DR, Meneghetti CM, Parker K, Shaw JP, Deisseroth AB, Woodworth T. LeMaistre CF, et al. Among authors: parkinson dr. Lancet. 1991 May 11;337(8750):1124-5. doi: 10.1016/0140-6736(91)92788-4. Lancet. 1991. PMID: 1674015

3

Interleukin-2 in therapy of hematologic malignancies.

Sznol M, Parkinson DR. Sznol M, et al. Among authors: parkinson dr. Blood. 1994 Apr 15;83(8):2020-2. Blood. 1994. PMID: 8161773 Free article. No abstract available.

4

Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.

Yang SC, Grimm EA, Parkinson DR, Carinhas J, Fry KD, Mendiguren-Rodriguez A, Licciardello J, Owen-Schaub LB, Hong WK, Roth JA. Yang SC, et al. Among authors: parkinson dr. Cancer Res. 1991 Jul 15;51(14):3669-76. Cancer Res. 1991. PMID: 1648441 Clinical Trial.

5

Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies.

Weber J, Yang JC, Topalian SL, Parkinson DR, Schwartzentruber DS, Ettinghausen SE, Gunn H, Mixon A, Kim H, Cole D, et al. Weber J, et al. Among authors: parkinson dr. J Clin Oncol. 1993 Mar;11(3):499-506. doi: 10.1200/JCO.1993.11.3.499. J Clin Oncol. 1993. PMID: 7680375 Clinical Trial.

6

Lessons from the clinical trials of interleukin-2.

Parkinson DR. Parkinson DR. Nat Immun Cell Growth Regul. 1990;9(4):242-52. Nat Immun Cell Growth Regul. 1990. PMID: 2215513 Review.

7

Interleukin-2 in cancer therapy.

Parkinson DR. Parkinson DR. Semin Oncol. 1988 Dec;15(6 Suppl 6):10-26. Semin Oncol. 1988. PMID: 3061014 Review.

8

A phase I trial of intravenous interleukin-6 in patients with advanced cancer.

Weber J, Gunn H, Yang J, Parkinson D, Topalian S, Schwartzentruber D, Ettinghausen S, Levitt D, Rosenberg SA. Weber J, et al. J Immunother Emphasis Tumor Immunol. 1994 May;15(4):292-302. doi: 10.1097/00002371-199405000-00008. J Immunother Emphasis Tumor Immunol. 1994. PMID: 7520334 Clinical Trial.

9

Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease.

Atkins MB, Gould JA, Allegretta M, Li JJ, Dempsey RA, Rudders RA, Parkinson DR, Reichlin S, Mier JW. Atkins MB, et al. Among authors: parkinson dr. J Clin Oncol. 1986 Sep;4(9):1380-91. doi: 10.1200/JCO.1986.4.9.1380. J Clin Oncol. 1986. PMID: 3489080

10

Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center.

Parkinson DR, Talpaz M, Lee KH, Legha S, Markowitz AB, Itoh K, Balch CM, Murray JL, Zukiwski AA, Benjamin RS, et al. Parkinson DR, et al. Cancer Treat Rev. 1989 Jun;16 Suppl A:39-48. doi: 10.1016/0305-7372(89)90021-2. Cancer Treat Rev. 1989. PMID: 2670214 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

118 results

Search Page

Filters